6533b853fe1ef96bd12acc8c
RESEARCH PRODUCT
CD4 blockade directly inhibits mouse and human CD4+ T cell functions independent of Foxp3+ Tregs
Edgar SchmittC. T. MayerAmrita NandanT. SparwasserJulia M. HuntenburgN. Czelothsubject
T cellImmunologyPriming (immunology)Ki-1 Antigenchemical and pharmacologic phenomenaBiologyCD8-Positive T-LymphocytesLymphocyte ActivationT-Lymphocytes RegulatoryLymphocyte DepletionInterleukin 21MiceImmune systemmedicineImmune ToleranceImmunology and AllergyCytotoxic T cellAnimalsHumansIL-2 receptorCells CulturedAntilymphocyte SerumCell ProliferationMice Inbred BALB CFOXP3Forkhead Transcription Factorshemic and immune systemsDendritic CellsReceptors OX40medicine.diseaseTransplant rejectionMice Inbred C57BLmedicine.anatomical_structureImmunologyCD4 AntigensInterleukin-2description
CD4(+) helper T cells orchestrate protective immunity against pathogens, yet can also induce undesired pathologies including allergies, transplant rejection and autoimmunity. Non-depleting CD4-specific antibodies such as clone YTS177.9 were found to promote long-lasting T cell tolerance in animal models. Thus, CD4 blockade could represent a promising therapeutic approach for human autoimmune diseases. However, the mechanisms underlying anti-CD4-induced tolerance are incompletely resolved. Particularly, multiple immune cells express CD4 including Foxp3(+) regulatory T cells (Tregs) and dendritic cells (DCs), both controlling the activation of CD4(+)Foxp3(-) helper T cells. Utilizing mixed leukocyte reactions (MLRs) reflecting physiological interactions between T cells and DCs, we report that anti-CD4 treatment inhibits CD4(+)Foxp3(-) T cell proliferation in an IL-2-independent fashion. Notably, YTS177.9 binding induces a rapid internalization of CD4 on both CD4(+)Foxp3(-) T cells and Foxp3(+) Tregs. However, no expansion or activation of immunosuppressive CD4(+)Foxp3(+) Tregs was observed following anti-CD4 treatment. Additionally, cytokine production, maturation and T cell priming capacity of DCs are not affected by anti-CD4 exposure. In line with these data, the selective ablation of Foxp3(+) Tregs from MLRs by the use of diphtheria toxin (DT)-treated bacterial artificial chromosome (BAC)-transgenic DEREG mice completely fails to abrogate the suppressive activity of multiple anti-CD4 antibodies. Instead, tolerization is associated with the defective expression of various co-stimulatory receptors including OX40 and CD30, suggesting altered signaling through the TCR complex. Consistent with our findings in mice, anti-CD4 treatment renders human CD4(+) T cells tolerant in the absence of Tregs. Thus, our results establish that anti-CD4 antibodies can directly tolerize pathogenic CD4(+)Foxp3(-) helper T cells. This has important implications for the treatment of human inflammatory diseases.
year | journal | country | edition | language |
---|---|---|---|---|
2013-12-01 |